Fig. 6

AGMAT was negatively correlated with SFRP2 + CAF infiltration and External validation. (A) The t-SNE plots of 7 cell types in the validation cohort. (B) Feature genes of each CAF clusters in the validation cohort. (C-F) ssGSEA scores of myCAFs, apCAFs, iCAFs, and vCAFs in 5 CAF clusters. (G-H) SFRP2 + CAF ssGSEA scores of responder and non-responder in GSE28702 and GSE106584. (I) Dot plot showing RIMKLB, AGMAT, and GPX3 gene expression across the 7 cell subtypes in GSE178341. (J) The proportion of CAF clusters between low- and high-AGMAT groups. (K) Correlation analysis between AGMAT expression and ssGSEA scores of SFRP2 + CAFs in TCGA and GSE39582 cohorts. (L) Spatial cell charting and AGMAT expression of ST_CRC1. (M) Spatial cell charting of ST_CRC2 and ST_CRC3 using CellTrek. (N) Boxplot showing the average k-distance from different cell types to cancer cells in three ST_CRC samples. (O) AGMAT expression level between oxaliplatin-resistant and oxaliplatin-sensitive groups. (P) Oxaliplatin sensitivity analysis between low- and high-AGMAT groups in TCGA cohort. (Q) The mRNA expression of AGMAT was detected by qPCR in HCT116 cells treated with oxaliplatin. (R) Cytotoxicity of oxaliplatin and/or AGMAT in HCT116 cells. Unpaired t-test were used to compare two groups. *p<0.05, *p<0.01, *p<0.001